Innovative Targeted and Immune-Mediated Cancer Therapies
Pipeline
Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients
Science
Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics
News
August 11,
2025
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
June 30,
2025
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
June 11,
2025
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
Events
Tuesday,
December 3RD,
2024
at
9:00 AM
Eastern
Piper Sandler 36th Annual Healthcare Conference
Listen: Webcast
Thursday,
June 20TH,
2024
at
8:30 AM
Eastern
Amezalpat (TPST-1120) Global Randomized Phase 1b/2 Combination Study Update Call
Listen: Webcast
Download: Presentation [pdf]
Wednesday,
October 11TH,
2023
at
8:30 AM
Eastern
TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call
Listen: Webcast
Download: Presentation [pdf]